Loading…

An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo -Expanded Natural Killer Cells

Recent advances in cellular therapies for patients with cancer, including checkpoint blockade and -expanded, tumor-specific T cells, have demonstrated that targeting the immune system is a powerful approach to the elimination of tumor cells. Clinical efforts have also demonstrated limitations, howev...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2018-02, Vol.9, p.150-150
Main Authors: Lieberman, Nicole A P, DeGolier, Kole, Haberthur, Kristen, Chinn, Harrison, Moyes, Kara W, Bouchlaka, Myriam N, Walker, Kirsti L, Capitini, Christian M, Crane, Courtney A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c462t-ed603b58b1475fa597ddedfc008df9e12fb0b324a13ad4ebbe80b9a270f0a123
cites cdi_FETCH-LOGICAL-c462t-ed603b58b1475fa597ddedfc008df9e12fb0b324a13ad4ebbe80b9a270f0a123
container_end_page 150
container_issue
container_start_page 150
container_title Frontiers in immunology
container_volume 9
creator Lieberman, Nicole A P
DeGolier, Kole
Haberthur, Kristen
Chinn, Harrison
Moyes, Kara W
Bouchlaka, Myriam N
Walker, Kirsti L
Capitini, Christian M
Crane, Courtney A
description Recent advances in cellular therapies for patients with cancer, including checkpoint blockade and -expanded, tumor-specific T cells, have demonstrated that targeting the immune system is a powerful approach to the elimination of tumor cells. Clinical efforts have also demonstrated limitations, however, including the potential for tumor cell antigenic drift and neoantigen formation, which promote tumor escape and recurrence, as well as rapid onset of T cell exhaustion . These findings suggest that antigen unrestricted cells, such as natural killer (NK) cells, may be beneficial for use as an alternative to or in combination with T cell based approaches. Although highly effective in lysing transformed cells, to date, few clinical trials have demonstrated antitumor function or persistence of transferred NK cells. Several recent studies describe methods to expand NK cells for adoptive transfer, although the effects of expansion are not fully understood. We therefore explored the impact of a clinically validated 12-day expansion protocol using a K562 cell line expressing membrane-bound IL-15 and 4-1BB ligand with high-dose soluble IL-2 on the phenotype and functions of NK cells from healthy donors. Following expansions using this protocol, we found expression of surface proteins that implicate preferential expansion of NK cells that are not fully mature, as is typically associated with highly cytotoxic NK cell subsets. Despite increased expression of markers associated with functional exhaustion in T cells, we found that -expanded NK cells retained cytokine production capacity and had enhanced tumor cell cytotoxicity. The preferential expansion of an NK cell subset that is phenotypically immature and functionally pleiotropic suggests that adoptively transferred cells may persist better when compared with previous methods using this approach. expansion does not quell killer immunoglobulin-like receptor diversity, allowing responsiveness to various factors that may influence activation and inhibition. Collectively, our data suggest that in addition to robust NK cell expansion that has been described using this method, expanded NK cells may represent an ideal cell therapy that is longer lived, highly potent, and responsive to an array of activating and inhibitory signals.
doi_str_mv 10.3389/fimmu.2018.00150
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_f1884bd5b0034f119a94708499566cb5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_f1884bd5b0034f119a94708499566cb5</doaj_id><sourcerecordid>2004390816</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-ed603b58b1475fa597ddedfc008df9e12fb0b324a13ad4ebbe80b9a270f0a123</originalsourceid><addsrcrecordid>eNpVkc1vFCEYhydGY5vauyfD0cuuL1-zcDFpNtva2FYP1SsBBrbUGRiZmab738vs1qblAoHf-7zAU1UfMSwpFfKLD103LQlgsQTAHN5Ux7iu2YISwt6-WB9Vp8NwD2UwSSnl76sjIhmvORXHVTyL6Fe0aerbELcoebTWMcVgdYt-3rmYxl0fLLrW-Y_LA9KxQedTtGNIcU6k0UW7m8s2j-h3eEhosXnsS8o16EaPUy6h76FtXUZr17bDh-qd1-3gTp_mk-r2fHO7_ra4-nFxuT67WlhWk3Hhmhqo4cJgtuJec7lqCtFbANF46TDxBgwlTGOqG-aMcQKM1GQFHjQm9KS6PGCbpO9Vn0On804lHdR-I-Wt0nkMtnXKYyGYabgBoMxjLLVkKxBMSl7X1vDC-npg9ZPpXGNdHMurXkFfn8Rwp7bpQXEBmMEM-PwEyOnv5IZRdWGw5Td0dGkaFCliqASB6xKFQ9TmNAzZ-ec2GNQsXe2lq1m62ksvJZ9eXu-54L9i-g8feKn8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2004390816</pqid></control><display><type>article</type><title>An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo -Expanded Natural Killer Cells</title><source>PubMed Central Free</source><creator>Lieberman, Nicole A P ; DeGolier, Kole ; Haberthur, Kristen ; Chinn, Harrison ; Moyes, Kara W ; Bouchlaka, Myriam N ; Walker, Kirsti L ; Capitini, Christian M ; Crane, Courtney A</creator><creatorcontrib>Lieberman, Nicole A P ; DeGolier, Kole ; Haberthur, Kristen ; Chinn, Harrison ; Moyes, Kara W ; Bouchlaka, Myriam N ; Walker, Kirsti L ; Capitini, Christian M ; Crane, Courtney A</creatorcontrib><description>Recent advances in cellular therapies for patients with cancer, including checkpoint blockade and -expanded, tumor-specific T cells, have demonstrated that targeting the immune system is a powerful approach to the elimination of tumor cells. Clinical efforts have also demonstrated limitations, however, including the potential for tumor cell antigenic drift and neoantigen formation, which promote tumor escape and recurrence, as well as rapid onset of T cell exhaustion . These findings suggest that antigen unrestricted cells, such as natural killer (NK) cells, may be beneficial for use as an alternative to or in combination with T cell based approaches. Although highly effective in lysing transformed cells, to date, few clinical trials have demonstrated antitumor function or persistence of transferred NK cells. Several recent studies describe methods to expand NK cells for adoptive transfer, although the effects of expansion are not fully understood. We therefore explored the impact of a clinically validated 12-day expansion protocol using a K562 cell line expressing membrane-bound IL-15 and 4-1BB ligand with high-dose soluble IL-2 on the phenotype and functions of NK cells from healthy donors. Following expansions using this protocol, we found expression of surface proteins that implicate preferential expansion of NK cells that are not fully mature, as is typically associated with highly cytotoxic NK cell subsets. Despite increased expression of markers associated with functional exhaustion in T cells, we found that -expanded NK cells retained cytokine production capacity and had enhanced tumor cell cytotoxicity. The preferential expansion of an NK cell subset that is phenotypically immature and functionally pleiotropic suggests that adoptively transferred cells may persist better when compared with previous methods using this approach. expansion does not quell killer immunoglobulin-like receptor diversity, allowing responsiveness to various factors that may influence activation and inhibition. Collectively, our data suggest that in addition to robust NK cell expansion that has been described using this method, expanded NK cells may represent an ideal cell therapy that is longer lived, highly potent, and responsive to an array of activating and inhibitory signals.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2018.00150</identifier><identifier>PMID: 29456538</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>4-1BB Ligand - immunology ; adoptive transfer ; clinical product ; ex vivo expansion ; Humans ; Immunology ; immunotherapy ; Interleukin-15 - immunology ; Interleukin-2 - immunology ; K562 Cells ; Killer Cells, Natural - immunology ; natural killer cells ; Phenotype ; phenotypic analysis</subject><ispartof>Frontiers in immunology, 2018-02, Vol.9, p.150-150</ispartof><rights>Copyright © 2018 Lieberman, DeGolier, Haberthur, Chinn, Moyes, Bouchlaka, Walker, Capitini and Crane. 2018 Lieberman, DeGolier, Haberthur, Chinn, Moyes, Bouchlaka, Walker, Capitini and Crane</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-ed603b58b1475fa597ddedfc008df9e12fb0b324a13ad4ebbe80b9a270f0a123</citedby><cites>FETCH-LOGICAL-c462t-ed603b58b1475fa597ddedfc008df9e12fb0b324a13ad4ebbe80b9a270f0a123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801405/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801405/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29456538$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lieberman, Nicole A P</creatorcontrib><creatorcontrib>DeGolier, Kole</creatorcontrib><creatorcontrib>Haberthur, Kristen</creatorcontrib><creatorcontrib>Chinn, Harrison</creatorcontrib><creatorcontrib>Moyes, Kara W</creatorcontrib><creatorcontrib>Bouchlaka, Myriam N</creatorcontrib><creatorcontrib>Walker, Kirsti L</creatorcontrib><creatorcontrib>Capitini, Christian M</creatorcontrib><creatorcontrib>Crane, Courtney A</creatorcontrib><title>An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo -Expanded Natural Killer Cells</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>Recent advances in cellular therapies for patients with cancer, including checkpoint blockade and -expanded, tumor-specific T cells, have demonstrated that targeting the immune system is a powerful approach to the elimination of tumor cells. Clinical efforts have also demonstrated limitations, however, including the potential for tumor cell antigenic drift and neoantigen formation, which promote tumor escape and recurrence, as well as rapid onset of T cell exhaustion . These findings suggest that antigen unrestricted cells, such as natural killer (NK) cells, may be beneficial for use as an alternative to or in combination with T cell based approaches. Although highly effective in lysing transformed cells, to date, few clinical trials have demonstrated antitumor function or persistence of transferred NK cells. Several recent studies describe methods to expand NK cells for adoptive transfer, although the effects of expansion are not fully understood. We therefore explored the impact of a clinically validated 12-day expansion protocol using a K562 cell line expressing membrane-bound IL-15 and 4-1BB ligand with high-dose soluble IL-2 on the phenotype and functions of NK cells from healthy donors. Following expansions using this protocol, we found expression of surface proteins that implicate preferential expansion of NK cells that are not fully mature, as is typically associated with highly cytotoxic NK cell subsets. Despite increased expression of markers associated with functional exhaustion in T cells, we found that -expanded NK cells retained cytokine production capacity and had enhanced tumor cell cytotoxicity. The preferential expansion of an NK cell subset that is phenotypically immature and functionally pleiotropic suggests that adoptively transferred cells may persist better when compared with previous methods using this approach. expansion does not quell killer immunoglobulin-like receptor diversity, allowing responsiveness to various factors that may influence activation and inhibition. Collectively, our data suggest that in addition to robust NK cell expansion that has been described using this method, expanded NK cells may represent an ideal cell therapy that is longer lived, highly potent, and responsive to an array of activating and inhibitory signals.</description><subject>4-1BB Ligand - immunology</subject><subject>adoptive transfer</subject><subject>clinical product</subject><subject>ex vivo expansion</subject><subject>Humans</subject><subject>Immunology</subject><subject>immunotherapy</subject><subject>Interleukin-15 - immunology</subject><subject>Interleukin-2 - immunology</subject><subject>K562 Cells</subject><subject>Killer Cells, Natural - immunology</subject><subject>natural killer cells</subject><subject>Phenotype</subject><subject>phenotypic analysis</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc1vFCEYhydGY5vauyfD0cuuL1-zcDFpNtva2FYP1SsBBrbUGRiZmab738vs1qblAoHf-7zAU1UfMSwpFfKLD103LQlgsQTAHN5Ux7iu2YISwt6-WB9Vp8NwD2UwSSnl76sjIhmvORXHVTyL6Fe0aerbELcoebTWMcVgdYt-3rmYxl0fLLrW-Y_LA9KxQedTtGNIcU6k0UW7m8s2j-h3eEhosXnsS8o16EaPUy6h76FtXUZr17bDh-qd1-3gTp_mk-r2fHO7_ra4-nFxuT67WlhWk3Hhmhqo4cJgtuJec7lqCtFbANF46TDxBgwlTGOqG-aMcQKM1GQFHjQm9KS6PGCbpO9Vn0On804lHdR-I-Wt0nkMtnXKYyGYabgBoMxjLLVkKxBMSl7X1vDC-npg9ZPpXGNdHMurXkFfn8Rwp7bpQXEBmMEM-PwEyOnv5IZRdWGw5Td0dGkaFCliqASB6xKFQ9TmNAzZ-ec2GNQsXe2lq1m62ksvJZ9eXu-54L9i-g8feKn8</recordid><startdate>20180202</startdate><enddate>20180202</enddate><creator>Lieberman, Nicole A P</creator><creator>DeGolier, Kole</creator><creator>Haberthur, Kristen</creator><creator>Chinn, Harrison</creator><creator>Moyes, Kara W</creator><creator>Bouchlaka, Myriam N</creator><creator>Walker, Kirsti L</creator><creator>Capitini, Christian M</creator><creator>Crane, Courtney A</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180202</creationdate><title>An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo -Expanded Natural Killer Cells</title><author>Lieberman, Nicole A P ; DeGolier, Kole ; Haberthur, Kristen ; Chinn, Harrison ; Moyes, Kara W ; Bouchlaka, Myriam N ; Walker, Kirsti L ; Capitini, Christian M ; Crane, Courtney A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-ed603b58b1475fa597ddedfc008df9e12fb0b324a13ad4ebbe80b9a270f0a123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>4-1BB Ligand - immunology</topic><topic>adoptive transfer</topic><topic>clinical product</topic><topic>ex vivo expansion</topic><topic>Humans</topic><topic>Immunology</topic><topic>immunotherapy</topic><topic>Interleukin-15 - immunology</topic><topic>Interleukin-2 - immunology</topic><topic>K562 Cells</topic><topic>Killer Cells, Natural - immunology</topic><topic>natural killer cells</topic><topic>Phenotype</topic><topic>phenotypic analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lieberman, Nicole A P</creatorcontrib><creatorcontrib>DeGolier, Kole</creatorcontrib><creatorcontrib>Haberthur, Kristen</creatorcontrib><creatorcontrib>Chinn, Harrison</creatorcontrib><creatorcontrib>Moyes, Kara W</creatorcontrib><creatorcontrib>Bouchlaka, Myriam N</creatorcontrib><creatorcontrib>Walker, Kirsti L</creatorcontrib><creatorcontrib>Capitini, Christian M</creatorcontrib><creatorcontrib>Crane, Courtney A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lieberman, Nicole A P</au><au>DeGolier, Kole</au><au>Haberthur, Kristen</au><au>Chinn, Harrison</au><au>Moyes, Kara W</au><au>Bouchlaka, Myriam N</au><au>Walker, Kirsti L</au><au>Capitini, Christian M</au><au>Crane, Courtney A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo -Expanded Natural Killer Cells</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2018-02-02</date><risdate>2018</risdate><volume>9</volume><spage>150</spage><epage>150</epage><pages>150-150</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Recent advances in cellular therapies for patients with cancer, including checkpoint blockade and -expanded, tumor-specific T cells, have demonstrated that targeting the immune system is a powerful approach to the elimination of tumor cells. Clinical efforts have also demonstrated limitations, however, including the potential for tumor cell antigenic drift and neoantigen formation, which promote tumor escape and recurrence, as well as rapid onset of T cell exhaustion . These findings suggest that antigen unrestricted cells, such as natural killer (NK) cells, may be beneficial for use as an alternative to or in combination with T cell based approaches. Although highly effective in lysing transformed cells, to date, few clinical trials have demonstrated antitumor function or persistence of transferred NK cells. Several recent studies describe methods to expand NK cells for adoptive transfer, although the effects of expansion are not fully understood. We therefore explored the impact of a clinically validated 12-day expansion protocol using a K562 cell line expressing membrane-bound IL-15 and 4-1BB ligand with high-dose soluble IL-2 on the phenotype and functions of NK cells from healthy donors. Following expansions using this protocol, we found expression of surface proteins that implicate preferential expansion of NK cells that are not fully mature, as is typically associated with highly cytotoxic NK cell subsets. Despite increased expression of markers associated with functional exhaustion in T cells, we found that -expanded NK cells retained cytokine production capacity and had enhanced tumor cell cytotoxicity. The preferential expansion of an NK cell subset that is phenotypically immature and functionally pleiotropic suggests that adoptively transferred cells may persist better when compared with previous methods using this approach. expansion does not quell killer immunoglobulin-like receptor diversity, allowing responsiveness to various factors that may influence activation and inhibition. Collectively, our data suggest that in addition to robust NK cell expansion that has been described using this method, expanded NK cells may represent an ideal cell therapy that is longer lived, highly potent, and responsive to an array of activating and inhibitory signals.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>29456538</pmid><doi>10.3389/fimmu.2018.00150</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2018-02, Vol.9, p.150-150
issn 1664-3224
1664-3224
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_f1884bd5b0034f119a94708499566cb5
source PubMed Central Free
subjects 4-1BB Ligand - immunology
adoptive transfer
clinical product
ex vivo expansion
Humans
Immunology
immunotherapy
Interleukin-15 - immunology
Interleukin-2 - immunology
K562 Cells
Killer Cells, Natural - immunology
natural killer cells
Phenotype
phenotypic analysis
title An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo -Expanded Natural Killer Cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T21%3A01%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20Uncoupling%20of%20Canonical%20Phenotypic%20Markers%20and%20Functional%20Potency%20of%20Ex%20Vivo%20-Expanded%20Natural%20Killer%20Cells&rft.jtitle=Frontiers%20in%20immunology&rft.au=Lieberman,%20Nicole%20A%20P&rft.date=2018-02-02&rft.volume=9&rft.spage=150&rft.epage=150&rft.pages=150-150&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2018.00150&rft_dat=%3Cproquest_doaj_%3E2004390816%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-ed603b58b1475fa597ddedfc008df9e12fb0b324a13ad4ebbe80b9a270f0a123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2004390816&rft_id=info:pmid/29456538&rfr_iscdi=true